Northwest Biotherapeutics and NHSBT Announce Collaboration on DCVax®-L Production Support
Northwest Biotherapeutics and the UK National Health Service Blood and Transplant (NHSBT) have announced a collaboration to support the production of DCVax®-L therapies. The agreement focuses on critical manufacturing processes.
Northwest Biotherapeutics, a biotechnology firm developing personalized immune therapies for solid tumors, has partnered with the UK National Health Service Blood and Transplant (NHSBT). The collaboration is set to provide support for the manufacturing processes of DCVax®-L, a personalized immunotherapy candidate.
The agreement aims to bolster the production capabilities and efficiency for DCVax®-L, which is Northwest Biotherapeutics' therapy targeting solid tumor cancers. This partnership with NHSBT is expected to enhance the manufacturing infrastructure necessary for the treatment's broader availability.
Key aspects of the collaboration will involve optimizing manufacturing steps, including those related to blood component handling and cell processing. NHSBT's established expertise in blood transfusion services is anticipated to contribute significantly to ensuring the quality and consistency of the DCVax®-L product.
Specific financial terms and timelines for the collaboration have not been disclosed. Northwest Biotherapeutics' stock trades on the OTCQB market under the ticker symbol NWBO.